AbbVie Inc.
NYSE:ABBV · New York Stock Exchange
-$4.65 today
Vol 5.08M · Avg 6.47M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-129.2%
avg 38.6%
ROIC
13.0%
avg 12.0%
ROA
3.2%
avg 6.7%
Analysis
ROIC is currently the strongest return metric at 13.0% versus its period average of 12.0%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Robert A. Michael | Chief Executive Officer & Chairman of the Board | $7.42M | — | 56 | $10,369.00 | <0.01% |
Jeffrey Ryan Stewart | Executive Vice President & Chief Commercial Officer | $5.00M | — | 57 | $2,654.00 | <0.01% |
Azita Saleki-Gerhardt | Executive Vice President & Chief Operating Officer | $4.07M | — | 63 | $197,794.00 | 0.01% |
Scott T. Reents | Executive Vice President & Chief Financial Officer | $3.95M | — | 58 | $38,777.00 | <0.01% |
Demetris D. Crum | Executive Vice President & Chief Human Resources Officer | $3.84M | — | 45 | $7,914.00 | <0.01% |
Roopal Thakkar | Executive Vice President of Research and Development & Chief Scientific Officer | $3.56M | — | 54 | $52,376.00 | <0.01% |
Elizabeth Shea | Senior Vice President of Investor Relations | — | — | — | — | — |
Nicholas J. Donoghoe | Executive Vice President and Chief Business & Strategy Officer | — | — | 45 | $74,430.00 | <0.01% |
Perry C. Siatis | Executive Vice President, General Counsel & Secretary | — | — | 51 | $17,510.00 | <0.01% |
Wulff-Erik von Borcke | Senior Vice President & President of Oncology | — | — | — | — | — |
Linda Ray | Senior VP & Chief Information Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
8
$21.79M
Net Sentiment
$21.79M
Net selling
Most Active
Siatis Perry C
4 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 8 sells worth $21.79M over the last 12 months. That adds up to net selling of $21.79M. Siatis Perry C was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -2.2% | +13.2% (15yr)5 analysts |
| Revenue | N/A | N/A | +7.5% | +9.0% (15yr)12 analysts |
| Net Income | N/A | N/A | -0.8% | +13.8% (15yr)12 analysts |
| EBIT | N/A | N/A | +9.0% | +5.3% (15yr)12 analysts |
Analysis
Recent growth has been strongest in EBIT at +9.0% over three years. Forward estimates point to Net Income at +13.8% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Johnson & Johnson
NYSE:JNJ
$552.22B
UnitedHealth Group Incorporated
NYSE:UNH
$366.18B
Merck & Co., Inc.
NYSE:MRK
$282.04B
Novartis AG
NYSE:NVS
$281.58B
AstraZeneca PLC
NYSE:AZN
$271.29B
Novo Nordisk A/S
NYSE:NVO
$191.37B
Amgen Inc.
NASDAQ:AMGN
$180.82B
Gilead Sciences, Inc.
NASDAQ:GILD
$152.65B
Pfizer Inc.
NYSE:PFE
$143.83B
Sanofi
NASDAQ:SNY
$101.50B
Who manages ABBV?
AbbVie Inc. (ABBV) lists 11 active executives. The top listed executive is Elizabeth Shea, Senior Vice President of Investor Relations.
Are ABBV insiders buying or selling?
Recent insider activity shows net selling of $72.41M.
Explore More
Continue the stock analysis
Jump to another research area for this company.